|Articles|September 2, 2020
AstraZeneca COVID-19 vaccine to US Phase 3 trial
Author(s)Lindsey Carr, Editor
According a press release and a recent article from Drug Topics, AstraZeneca’s investigational vaccine candidate AZD12222 expanded into a phase 3 clinical trial.
Advertisement
The trial is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
Up to 30,000 adults aged 18 years or older will be enrolled to assess the safety and immunogenicity of AZD1222, which was co-invented by the University of Oxford and Vaccitech.
For more information, read the full article from
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Diagnosing PMOS in adolescents
2
FDA working with manufacturers to increase access to estradiol transdermal patches
3
ACOG's 2026-27 respiratory virus immunization recommendations in pregnancy, postpartum
4
From PCOS to PMOS: A welcome and more inclusive name
5